However, in total CD4+ T cells, there was a significant reduction in Eomes−Tbet−CD4+ T cells between baseline (median: 79.0%; IQR, 21.2–93.1) and week 2 (median: 65.5%; IQR, 15.3–84.4) (P = .02) and baseline and week 4 (median: 54.5%; IQR, 21.8–94.5) (P = .009) in TB-IRIS patients. This evidence concerns the gene CD4 and tuberculosis.